Medera And Novoheart Collaborate With Physician-Scientists At University Of California San Diego School Of Medicine And Mayo Clinic To Develop Mini-Heart Models Aimed At Transforming Treatment For HLHS

• First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatments
• Partnership aims to improve survival and quality of life for pediatric HLHS patients by developing new tools that can identify which children will potentially benefit most from surgery, transplantation, or novel therapies
• Leveraging Novoheart's proprietary mini-Heart Platform, this partnership aligns with emerging FDA guidelines supporting human-relevant, animal-free drug development
   

BOSTON and SAN DIEGO and ROCHESTER, Minn., June 24, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, and Novoheart, its wholly owned pre-clinical subsidiary pioneering human-based cardiac tissue engineering for disease modelling and drug screening, today announced a groundbreaking collaboration with physician-scientists at the University of California San Diego School of Medicine and Mayo Clinic. The goal of the partnership is to develop the first human mini-heart models of hypoplastic left heart syndrome (HLHS) using stem cells from real patients and improve the understanding of this disease with the goal of developing more personalized treatment strategies for children born with this devastating condition.